key: cord-1032663-uxat4bsx authors: Pranata, Raymond; Huang, Ian; Raharjo, Sunu Budhi title: Incidence and impact of cardiac arrhythmias in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis date: 2020-08-16 journal: Indian Pacing Electrophysiol J DOI: 10.1016/j.ipej.2020.08.001 sha: e43e9921800a50cf809686994e56b62b64a1029e doc_id: 1032663 cord_uid: uxat4bsx BACKGROUND: Studies have shown that cardiac arrhythmias may occur in up to 44% of patients with severe coronavirus disease 2019 (COVID-19) and has been associated with an increased risk of death. This systematic review and meta-analysis aimed to evaluate the incidence of cardiac arrhythmias in patients with COVID-19 and their implications on patient prognosis. METHODS: We performed a systematic literature search from PubMed, SCOPUS, Europe PMC, Cochrane Central Databases, and Google Scholar + Preprint Servers. The primary endpoint of the study was poor outcomes including mortality, severe COVID-19, and the need for ICU care. RESULTS: A total of 4 studies including 784 patients were analyzed. The incidence of arrhythmia in patients with COVID-19 was 19% (9–28%; I(2): 91.45). Arrhythmia occurred in 48% (38–57%; I(2): 48.08) of patients with poor outcome and 6% (1–12%; I(2): 85.33%) of patients without poor outcome. Patients with COVID-19 experiencing arrhythmia had an increased risk of poor outcome (RR 7.96 [3.77, 16.81], p < 0.001; I(2): 71.1%). The funnel-plot analysis showed an asymmetrical funnel plot with most of the studies on the right side of the effect estimate. The regression-based Egger's test showed indication of small-study effects (p = 0.001). CONCLUSION: Cardiac arrhythmias were significantly associated with an increased risk of poor outcome in COVID-19. Arrhythmias were observed in 19% of patients with COVID-19 and in 48% of patients with COVID-19 and poor outcomes. Coronavirus disease 2019 (COVID- 19) was declared pandemic, and at the time this paper was written, it has infected more than 4.7 million people and caused more than 300.000 deaths. [1] Even though most of the infected patients have mild or no symptoms, some of them develop severe pneumonia, acute respiratory distress syndrome, multi-organ failure, and death. Factors such as age, smoking, diabetes, hypertension, and cardiovascular diseases are associated with severity and mortality in patients with COVID-19. [2] [3] [4] [5] [6] Previously, influenza epidemics have been shown to be associated with an increased risk of ventricular arrhythmia in patients with implantable cardiac defibrillators, [7] indicating that respiratory-borne infections might also be related to cardiovascular manifestations. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been shown to cause cardiac injury and cytokine storm, which may lead to cardiac arrhythmias. [8, 9] A study has shown that cardiac arrhythmias may occur in up to 44% of patients with severe COVID-19, [10] and has been associated with an increased risk of death. [11] This systematic review and meta-analysis aimed to evaluate the incidence of cardiac arrhythmias in patients with COVID-19 and their implications on patient prognosis. We included all research articles about adult patients diagnosed with COVID-19 with information on arrhythmia as a complication and clinical grouping or outcome of clinically validated definition of severe COVID-19, death, or ICU care. The following types of articles were excluded: articles other than original research (e.g., review articles, letters, or J o u r n a l P r e -p r o o f commentaries), original research with samples below 20 or case reports and series, articles not in English language, and articles on research in pediatric populations (17 years of age or younger). We systematically searched PubMed, SCOPUS, Europe PMC, Cochrane Central Databases, and Google Scholar + Preprint Servers with the search terms 1) "COVID-19" OR "SARS-CoV-2" AND "Characteristics" 2) "COVID-19" OR "SARS-CoV-2" AND "Arrhythmia". Duplicate results were removed. The remaining articles were independently screened by two authors (I. H. and R. P.) for the relevance of their abstracts. The full text of the remaining articles was assessed applying the inclusion and exclusion criteria. The search was finalized on April 14, 2020. The study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data extraction was performed independently by two of the authors (I. H. and R. P.). We used standardized forms that included author, year, study design, age, sex, cardiovascular diseases, history of hypertension and diabetes mellitus, respiratory comorbidities, antibiotics and antiviral use, glucocorticoid use, lymphopenia, follow-up duration, arrhythmia, mortality, ICU care, and severe COVID-19. The quality and risk of bias assessment of the included studies will be performed using the Newcastle-Ottawa Scale. The primary endpoint of the study was poor outcome, including mortality, severe COVID-19, and the need for ICU care. Severe COVID-19 was defined as patients who had any of the following features at the time of admission or after admission: (1) respiratory distress (≥ 30 J o u r n a l P r e -p r o o f breaths per min); (2) oxygen saturation at rest ≤ 93%; (3) ratio of partial pressure of arterial oxygen (PaO 2 ) to fractional concentration of oxygen inspired air (fiO 2 ) ≤ 300 mmHg; or (4) critical complication (respiratory failure, septic shock, and multiple organ dysfunction/failure). [12] The meta-analysis of studies was performed using Stata version 16. Meta-analysis of proportions was used to pool the incidence of arrhythmia in the groups. Dichotomous variables were calculated to obtain risk ratios (RRs) along with their 95% confidence intervals (CIs). Random effect models were used regardless of heterogeneity. The p-values were two-tailed and statistical significance was set at ≤ 0.05. A sensitivity analysis by leaveone-out was performed to test the robustness of the findings. To assess the small-study effect, we performed a regression-based Egger's test. Random-effects meta-regression was performed for gender, hypertension, diabetes, cardiovascular diseases, cerebrovascular diseases, respiratory comorbidities, and lymphopenia. We found 817 records and 509 remained after the removal of duplicates. A total of 461 records were excluded after screening the titles and abstracts. After assessing 48 articles for eligibility, we excluded 44 because of the following conditions: 1) there were no data on arrhythmia as complication (n = 43), and 2) arrhythmia was the baseline comorbidity, not an outcome (n = 1). As a result, 4 studies remained for qualitative synthesis and meta-analysis ( Figure 1 ). There were 784 patients from the 4 studies. [10, 11, 13, 14] . Baseline characteristics is displayed in Table 1 19 .88], p=0.12; I 2 : 81%, p=0.001) was not associated with poor outcome. The incidence of arrhythmia in patients with COVID-19 was 19% (9-28%; I 2 : 91.45, p < 0.001) ( Figure 2A ). Arrhythmia occurred in 48% (38-57%; I 2 : 48.08, p = 0.12) of patients with poor outcome ( Figure 2B ) and 6% (1-12%; I 2 : 85.33%) of patients without poor outcome ( Figure 2C ). Patients with COVID-19 experiencing arrhythmia had an increased risk of poor outcome (RR The association between arrhythmia and outcome in patients with COVID-19 did not vary significantly with age (p=0.840), male (p=0.220), hypertension (p=0.977), cardiovascular J o u r n a l P r e -p r o o f diseases (p=0.848), diabetes (p=0.139), respiratory comorbidities (p=0.729), and lymphopenia (p=0.084). The funnel-plot analysis showed an asymmetrical funnel plot with most of the studies on the right side of the effect estimate ( Figure 4 ). Regression-based Egger's test showed no indication of small-study effects (p = 0.001). This meta-analysis showed that the incidence of arrhythmia was significantly higher in patients with poor outcomes, hence a marker of poor prognosis. Cardiac arrhythmias occurred frequently in patients with COVID-19, and the percentage was even higher in those with poor outcomes. However, this topic remains to be explored and currently, the included studies did not specify the types of arrhythmia. Hence, the specific types of arrhythmia that increase mortality and severity of COVID-19 remain inconclusive. Defining the types of arrhythmia in patients with COVID-19 is important because of the frequent incidence and is strongly associated with poor prognosis. Providing details on the type of arrhythmia may help clinicians to discriminate the prognostic significance of the arrhythmia, allowing more precise risk stratification. Several baseline characteristics are also associated with poor outcome in this pooled studies. These factors include gender, hypertension, diabetes, cardiovascular diseases, and respiratory comorbidities which is accordance to our previous meta-analyses assessing these factors. [2] [3] [4] [5] [6] We performed meta-regression and found that the association between arrhythmia and poor outcome did not varied with the gender and other comorbidities, nevertheless the number of studies <10. Arrhythmia may be attributed to metabolic disarray, hypoxia, inflammation, or neurohormonal stress associated with SARS-CoV-2 infection. [15] Furthermore, COVID-19 induced coagulopathy may cause thrombosis leading to hypoxia. [16, 17] Additionally, which patients often present electrolyte abnormalities that may precipitate/exacerbate cardiac arrhythmias. [18] SARS-CoV-2 itself has been shown to cause cardiac injury signified by increase in cardiac biomarkers. [19, 20] After activation of the viral surface spike (S) protein of SARS-CoV-2 by the transmembrane protease serine 2 (TMPRSS2), the virus binds to angiotensin-converting enzyme 2 (ACE2), [21, 22] which has high affinity to the human receptor. [23, 24] The aforementioned enzyme is highly expressed in cardiac pericytes, [25] infection, and subsequent immune response may cause damage to the heart. Myocardial inflammation, ion channel dysfunction, electrophysiological and structural remodeling associated with viral myocarditis has been shown to cause life-threatening arrhythmias. [26] Evidence shows that the rise of troponin is accompanied by increased inflammatory biomarkers, indicating the possible role of cytokine storm in cardiac injury. [27] Systemic inflammation has been shown to prolong ventricular action potential duration through disturbance of the potassium channel. [28] Interleukin-6, tumor necrosis factor alpha, and interleukin-1 may prolong the action potential duration through interplay with cardiomyocytes ion channels. [29] Elevated interleukin-6 during systemic inflammation may cause QT prolongation, which increases the risk for torsades de pointes. [30] Furthermore, QT-prolonging drugs are frequently used in the management of COVID-19, synergistically amplifying the risk of cardiac arrhythmias. Drugs such as azithromycin and hydroxychloroquine are associated with QT prolongation. [31, 32] Azithromycin is known to prolong the QT interval [33] and increase the risk of cardiovascular death. [34] The antimalarial chloroquine is associated with prolonged QT interval with or without azithryomycin J o u r n a l P r e -p r o o f according to a randomized controlled trial from the Pfizer Labs. [35] Moreover, lopinavirritonavir, a combination of drugs commonly known as protease inhibitors (PI) and usually used as 2 nd -line drugs in treating HIV infection, is also recognized as arrhythmogenic and can prolong the QT interval. [36, 37] This systematic review and meta-analysis has several limitations. First, the types of cardiac arrhythmias were not described in the included studies. Second, the risk of publication bias was high, as indicated by the asymmetrical funnel plot analysis and statistically significant Egger's test. Third, most of the studies are from China and may not be generalizable to other populations. Fourth, the number of studies were limited and not divided into arrhythmias versus non-arrhythmias; hence, we were not able to assess the risk factors for cardiac arrhythmias in these patients. Fifth, the studies did not report the level of electrolytes. Sixth, the studies were mostly retrospective. The predictive power of metaregression analysis is weaker if the number of studies are <10. Nevertheless, this study emphasizes the clinical importance of arrhythmia in patients with COVID-19, and further studies should explore cardiac arrhythmias in these patients. Authors declare no Conflict of Interests for this article. The incidence of arrhythmia is 19% (A). Arrhythmia occurs in 48% (B) of the patients with poor outcomes and 6% (C) of the patients without poor outcomes. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report -95 Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and meta-regression Impact of Cerebrovascular and Cardiovascular Diseases on Mortality and Severity of COVID-19 -Systematic Review, Meta-analysis, and Meta-regression Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19 Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis Influenza epidemics are associated with an increased risk of ventricular arrythmia therapies in patients with implantable cardiac defibrillators Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China COVID-19, Arrhythmic Risk and Inflammation: Mind the Gap! Circulation Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease Report of the WHO-China Joint Mission on Coronavirus Disease 2019 ( COVID-19 ) Clinical features and outcomes of 221 patients with COVID-19 in Wuhan Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Patients in Wuhan Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a metaanalysis Multiorgan Failure With Emphasis on Acute Kidney Injury and Severity of COVID-19: Systematic Review and Meta-Analysis Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of . Hear Rhythm Cardiac injury is SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis Characterization of the receptorbinding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2 What Is the Arrhythmic Substrate in Viral Myocarditis? Insights from Clinical and Animal Studies Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes Azithromycin , cardiovascular risks , QTc interval prolongation , torsade de pointes , and regulatory issues : A narrative review based on the study of case reports Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society Cardiovascular Risks with Azithromycin and Other Antibacterial Drugs Azithromycin and the Risk of Cardiovascular Death Zithromax (azithromycin tablets) and azithromycin for oral suspension The Maladaptive Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir) on the Rat Heart QT prolongation in HIVpositive patients: Review article Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients 15 February 2020 100 vs 97.6 Arbidol: 5.9 vs Severe COVID-19 7 28 days Mean Duration Arbidol : 63.4 vs 65 Intensive Care Unit 7 Mean Duration: Not Reported Sample: 1 J o u r n a l P r e -p r o o f Patients with COVID-19 experiencing arrhythmia have an increased risk of poor outcome. The funnel-plot analysis shows an asymmetrical funnel plot with most of the studies on the right side of the effect estimate.J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f